Your browser doesn't support javascript.
loading
Unintended Consequences of Immune Therapy for Immune-Mediated Diseases: Paradoxical Psoriasis and Dupilumab-Associated Musculoskeletal Syndrome.
Wallace, Elizabeth B; Hughes, Catherine D; Menon, Bina; Kirkham, Bruce.
Afiliación
  • Wallace EB; E.B. Wallace, MD, Cherry Hills Dermatology, Englewood, Colorado, USA.
  • Hughes CD; C.D. Hughes, MD, Department of Rheumatology, Tallaght University Hospital, Dublin, Ireland.
  • Menon B; B. Menon, MD, Rheumatology Department, Guy's and St Thomas' Hospital Foundation Trust, London, UK.
  • Kirkham B; B. Kirkham, MD, Rheumatology Department, Guy's and St Thomas' Hospital Foundation Trust, and Kings College London, London, UK.
J Rheumatol ; 2024 Aug 01.
Article en En | MEDLINE | ID: mdl-39089826
ABSTRACT
Two presentations at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting focused on unintended consequences of immunomodulatory therapy for psoriasis (PsO). Dr. Elizabeth Wallace presented on unintended consequences of tumor necrosis factor inhibitors for treating PsO and other inflammatory disorders. These consequences include paradoxical PsO, which is defined as unexpected new PsO cases or worsening PsO symptoms seemingly induced by treatment. Dr. Bruce Kirkham focused on unintended consequences of dupilumab treatment, which can include a musculoskeletal syndrome similar to psoriatic arthritis.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Rheumatol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Rheumatol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos